Imagine trying to find the right key for a lock, but every lock is slightly different. Right now, doctors give the same kidney medicine to everyone, even though some people don't react well to it. This project finds specific signals in blood or urine to tell doctors exactly which drug will work for which person. It's like moving from a one-size-fits-all shirt to a custom-tailored suit for healthcare.
Current kidney disease treatments use a one-size-fits-all approach, leading to suboptimal efficacy for many patients. There is a lack of validated tools to match the right drug to the right patient in daily clinical practice.
The project is developing a roadmap for biomarker use and validated pharmacodynamic biomarkers, including the validation of uCLU for atrasentan treatment.
If you are a diagnostics company dealing with a lack of validated kidney disease markers — this project developed validated pharmacodynamic biomarkers that allow for the creation of precision testing kits. This enables the matching of patients to the most effective drug faster.
If you are a pharma company dealing with suboptimal efficacy in clinical trials — this project developed qualification procedures and pipelines for biomarkers. This helps identify the right patient subgroups to increase the success rate of drug trials.
If you are a clinic dealing with high costs of ineffective treatments — this project developed a roadmap for biomarker use in daily practice. This leads to increased cost-efficiency and better patient quality of life.
Based on available project data, specific pricing or implementation costs are not provided, though the project aims to increase overall cost-efficiency in treatment.
The project includes 3 industry partners and focuses on creating qualification procedures for the diagnostics industry, suggesting a path toward industrial scale.
Based on available project data, specific licensing terms are not mentioned, but the project validates biomarkers like uCLU for use in clinical practice.
The project specifically develops qualification procedures intended for use by regulatory authorities to bridge the gap between research and clinical use.
The project runs from 2023-01-01 to 2027-12-31, with initial validation studies like UVALID already completed in the first 18 months.
The consortium is well-balanced for translation, consisting of 17 partners across 9 countries. With 8 universities and 3 industry players (18% industry ratio), the project combines deep academic research with commercial viability. The presence of 5 'other' organizations and 1 SME suggests a broad network capable of handling both clinical trials and market implementation.
Contact Academisch Ziekenhuis Groningen in the Netherlands
Contact us to explore licensing opportunities for the validated uCLU biomarker.
